BioSpace News Archive

Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the Company will participate in the following virtual investor conferences in October: Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail, will participate in the Jefferies Gene Therapy/Editing Virtual Summit, including a fi

Complete Response Letter cites exposure levels (Cmax) in certain weight groups No additional clinical studies anticipated by Aquestive No Clinical Safety issues or Non-Clinical Chemistry, Manufacturing and Controls (CMC) issues identified Conference call and webcast today at 6:30 p.m. ET WARREN, N.J., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patien

Danaher Corporation announced a correction to the previously announced quarterly cash dividend payable on its 5.00% Series B Mandatory Convertible Preferred Stock.

Today, the U.S. Food and Drug Administration approved Nucala (mepolizumab) for adults and children aged 12 years and older with hypereosinophilic syndrome (HES) for six months or lon

Genelux closes on first tranche of a convertible debt and warrant financing of up to $20M to fund the continued clinical development of Olvi-Vec, its lead oncolytic immunotherapy candidate [25-September-2020] SAN DIEGO , Sept. 25, 2020 /PRNewswire/ -- Genelux Corporation, a privately-held clinical-stage immunotherapy company, today announced that it has entered into a

- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced CEO Fred Chereau will present at the Chardan Virtual Genetic Medicines Conference on Monday, October 5, 2020 at 11 AM, ET. A live audio webcast of the presentation will be available under the “Events and Presentations” section of LogicBio’s website. A replay of the present

MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced its results for the three and six-months ended June 30, 2020, which are also available on SEDAR ( www.sedar.com ). The Company reported revenue of $69,452 for the three months ended June 30, 2020, compared with revenue of $259,108 for the three months ended June 30, 2019. Revenue from SIAscopy™ of $31,029 for the second quarter was higher than

Alzheimer’s disease is the most common form of dementia with more than 40 million affected people worldwide. To this day, there are no existing therapies for the effective prevention or treatment of the disease